Abstract
In this work we propose a bone metastasis model using power law growth functions in order to describe the biochemical interactions between bone cells and cancer cells. Experimental studies indicate that bone remodeling cycles are different for human life stages: childhood, young adulthood, and adulthood. In order to include such differences in our study, we estimate the model parameter values for each human life stage via bifurcation analysis. Results reveal an intrinsic relationship between the active period of remodeling cycles and the proliferation of cancer cells. Subsequently, using optimal control theory we analyze a possible antigen receptor therapy as a new treatment for bone metastasis. Theoretical results such as existence of optimal solutions are proved. Numerical simulations for late stages of bone metastasis are presented and a discussion of our results is carried out.
Similar content being viewed by others
Notes
The vicious cycle comprises metastasis-derived signals that stimulate bone lining osteoblasts to proliferate and/or differentiate. In response to signals derived from the metastases, the bone lining osteoblasts express osteoclastogenic factors such as RANKL, which in turn, promotes the maturation of those precursors into active osteoclasts. Since bone is rich in growth factors (TGF\(-\beta \)), resorption by the osteoclasts results in the increased bioavailability of TGF\(-\beta \). Taken together, these osteoclast-generated factors facilitate the growth and expansion of the metastases thus completing the vicious cycle (Lynch 2011).
References
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A et al (2015) Human epidermal growth factor receptor 2 (her2)-specific chimeric antigen receptor-modified t cells for the immunotherapy of her2-positive sarcoma. J Clin Oncol 33(15):1688
Araujo A, Cook LM, Lynch CC, Basanta D (2014) An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer. Can Res 74(9):2391–2401
Ayati B, Edwards C, Webb G, Wikswo J (2010) A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease. Biol Direct 5(1):28
Bayliss L, Mahoney D, Monk P (2012) Normal bone physiology, remodelling and its hormonal regulation. Surgery (Oxford) 30(2):47–53
Bilezikian JP, Raisz LG, Martin TJ (2008) Principles of bone biology. Academic Press, New York
Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in car t-cell therapy. Mol Therapy-Oncolyt 3(16):011
Business Wire (2021) U.S. Food and Drug Administration approves Bristol Myers Squibb’s and Bluebird Bio’s Abecma (idecabtagene vicleucel), the first anti-Bcma car T cell therapy for relapsed or refractory multiple myeloma. https://www.businesswire.com/news/home/20210326005507/en/. Accessed 20 May 2021
Camacho A, Jerez S (2019) Bone metastasis treatment modeling via optimal control. J Math Biol 78(1–2):497–526
Camacho D, Pienta K (2014) A multi-targeted approach to treating bone metastases. Cancer Metastasis Rev 33(2–3):545–553
Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M (2010) Chimeric antigen receptor-engineered t cells for immunotherapy of cancer. J Biomed Biotechnol 2010:956304
Cook L, Araujo A, Pow-Sang J, Budzevich M, Basanta D, Lynch C (2016) Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer. Sci Rep 6(29):384
Eladdadi A, Kim P, Mallet D (2014) Mathematical models of tumor-immune system dynamics, vol 107. Springer, Berlin
Eriksen EF (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Dis 11(4):219–227
Farhat A, Jiang D, Cui D, Keller ET, Jackson TL (2017) An integrative model of prostate cancer interaction with the bone microenvironment. Math Biosci 294:1–14
Fleming W, Rishel R (2012) Deterministic and stochastic optimal control, vol 1. Springer, Berlin
Garzón-Alvarado DA (2012) A mathematical model for describing the metastasis of cancer in bone tissue. Comput Methods Biomech Biomed Eng 15(4):333–346
Ghaderi S, Lie R, Moster D, Ruud E, Syse A, Wesenberg F, Bjørge T (2012) Cancer in childhood, adolescence, and young adults: a population-based study of changes in risk of cancer death during four decades in norway. Cancer Cause Control 23(8):1297–1305
Gilham DE, Debets R, Pule M, Hawkins RE, Abken H (2012) Car-t cells and solid tumors: tuning t cells to challenge an inveterate foe. Trends Mol Med 18(7):377–384
Gonzalez H, Hagerling C, Werb Z (2018) Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 32(19–20):1267–1284
He Q, Liu Z, Liu Z, Lai Y, Zhou X, Weng J (2019) Tcr-like antibodies in cancer immunotherapy. J Hematol Oncol 12(1):99
Heaney RP (2001) Methods in nutrition science: the bone remodeling transient: interpreting interventions involving bone-related nutrients. Nutr Rev 59(10):327–334
Hillerdal V, Essand M (2015) Chimeric antigen receptor-engineered t cells for the treatment of metastatic prostate cancer. BioDrugs 29(2):75–89
Jackson HJ, Rafiq S, Brentjens RJ (2016) Driving car t-cells forward. Nat Rev Clin Oncol 13(6):370
Jerez S, Camacho A (2018) Bone metastasis modeling based on the interactions between the BMU and tumor cells. J Comput Appl Math 330:866–876
Jerez S, Chen B (2015) Stability analysis of a komarova type model for the interactions of osteoblast and osteoclast cells during bone remodeling. Math Biosci 264:29–37
Jilka RL (2003) Biology of the basic multicellular unit and the pathophysiology of osteoporosis. J Comput Appl Math 41(3):182–185
Jinnah AH, Zacks BC, Gwam CU, Kerr BA (2018) Emerging and established models of bone metastasis. Cancers 10(6):176
Juárez P, Guise T (2011) TGF-\(\beta \) in cancer and bone: implications for treatment of bone metastases. Bone 48(1):23–29
June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC (2018) Car t cell immunotherapy for human cancer. Science 359(6382):1361–1365
Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3(95):95ra73
Klebanoff C, Yamamoto T, Restifo N (2014) Immunotherapy: treatment of aggressive lymphomas with anti-cd19 car t cells. Nat Rev Clin Oncol 11(12):685–6
Koenders M, Saso R (2016) A mathematical model of cell equilibrium and joint cell formation in multiple myeloma. J Theor Biol 390:73–79
Komarova S, Smith R, Dixon S, Sims S, Wahl L (2003) Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 33(2):206–215
Lemos J, Caiado D, Coelho R, Vinga S (2016) Optimal and receding horizon control of tumor growth in myeloma bone disease. Biomed Signal Proces 24:128–134
Lenhart S, Workman J (2007) Optimal control applied to biological models. Chapman and Hall/CRC, Cambridge
Lo CH, Baratchart E, Basanta D, Lynch CC (2021) Computational modeling reveals a key role for polarized myeloid cells in controlling osteoclast activity during bone injury repair. Sci Rep 11(1):1–14
Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive t cells in patients with neuroblastoma. Blood J Am Soc Hematol 118(23):6050–6056
Lynch CC (2011) Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. Bone 48(1):44–53
Ma L, Dichwalkar T, Chang JY, Cossette B, Garafola D, Zhang AQ, Fichter M, Wang C, Liang S, Silva M et al (2019) Enhanced car-t cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365(6449):162–168
Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21(2):115–137
Mundy G (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584
Muñoz AI, Tello JI (2017) On a mathematical model of bone marrow metastatic niche. Math Biosci Eng 14(1):289
National Cancer Institute (2021) T cell transfer therapy. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy
Neilan RM, Lenhart S (2010) An introduction to optimal control with an application in disease modeling. In: Modeling paradigms and analysis of disease trasmission models, pp 67–81
Newick K, Moon E, Albelda S (2016) Chimeric antigen receptor t-cell therapy for solid tumors. Mol Ther Oncolyt 3(16):006
Ottewell PD (2016) The role of osteoblasts in bone metastasis. J Bone Oncol 5(3):124–127
Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 133:571–573
Parfitt AM (1994) Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55(3):273–286
Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified t cells in chronic lymphoid leukemia. N Engl J Med 365:725–733
Randall R, Lewis V, Weber K (2016) Metastatic bone disease. An integrated approach to patient care. Springer, New York
Rhodes A, Hillen T (2019) A mathematical model for the immune-mediated theory of metastasis. J Theor Biol 482(109):999
Rhodes A, Hillen T (2020) Implications of immune-mediated metastatic growth on metastatic dormancy, blow-up, early detection, and treatment. J Math Biol 81(3):799–843
Rosenberg S (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8(10):577
Ryser M, Komarova S, Nigam N (2010) The cellular dynamics of bone remodeling: a mathematical model. SIAM J Appl Math 70(6):1899–1921
Sarkar RR, Gloude NJ, Schiff D, Murphy JD (2019) Cost-effectiveness of chimeric antigen receptor t-cell therapy in pediatric relapsed/refractory b-cell acute lymphoblastic leukemia. JNCI J Natl Cancer Inst 111(7):719–726
Savageau MA (1988) Introduction to S-systems and the underlying power-law formalism. Math Comput Model 11:546–551
Sousa S, Clézardin P (2018) Bone-targeted therapies in cancer-induced bone disease. Calcif Tissue Int 102(2):227–250
US Food and Drug Administration (2021) Package insert—abecma. https://www.fda.gov/media/147055/download. Accessed 20 May 2021
Vera J, Balsa-Canto E, Wellstead P, Banga JR, Wolkenhauer O (2007) Power-law models of signal transduction pathways. Cell Signal 19(7):1531–1541
Voit E (1991) Canonical nonlinear modeling: S-systems approach to understanding complexity. Chapman & Hall, Cambridge
Walsh JS (2015) Normal bone physiology, remodelling and its hormonal regulation. Surgery (Oxford) 33(1):1–6
Wang RA, Li QL, Li ZS, Zheng PJ, Zhang HZ, Huang XF, Chi SM, Yang AG, Cui R (2013) Apoptosis drives cancer cells proliferate and metastasize. J Cell Mol Med 17(1):205–211
Weiner M, Weiner SL, Simone JV (2003) Childhood Cancer Survivorship: Improving Care and Quality of Life. Institute of Medicine (US) and National Research Council (US) National Cancer Policy Board. National Academies Press (US)
Wiggers SL, Pedersen P (2018) Routh-hurwitz-liénard-chipart criteria. Structural stability and vibration. Springer, Cham, pp 133–140
Zhao L, Cao Y (2019) Engineered t cell therapy for cancer in the clinic. Front Immunol 10:2250
Zumsande M, Stiefs D, Siegmund S, Gross T (2011) General analysis of mathematical models for bone remodeling. Bone 48(4):910–917
Zysk A, DeNichilo MO, Panagopoulos V, Zinonos I, Liapis V, Hay S, Ingman W, Ponomarev V, Atkins G, Findlay D et al (2017) Adoptive transfer of ex vivo expanded v\(\gamma \)9v\(\delta \)2 t cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer. Cancer Lett 386:141–150
Acknowledgements
This work was supported by Mexico CONACyT project CB2016-286437. A.K.M. was partially funded by an NCI PSON U01 CA244101. The authors thank Dr. Ryan Bishop for helpful discussions on the content of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendices
Bifurcation analysis
Based on the oscillations frequency, we carried out a bifurcation analysis with the numerical software XPPAUT/AUTO to give parameter values in the childhood, young adults and adulthood. Recalling that the solution of system (1) exhibits limit cycles or stable/unstable oscillations when equation (2) is satisfied. For this analysis, we study the effect of varying the parameters \(g_{11}\) and \(g_{22}\) on osteoclast steady states (c) in the bone remodeling model.
First, the bifurcation parameter was \(g_{11}\) and the other parameters were taken as \(g_{22}=0.0001\), \(g_{21} =1\) and \(g_{12}=-0.3\). Figure 11 shows the stability diagram of the equilibrium point and the Hopf bifurcation varying \(g_{11}\). The structure of the bifurcation diagram for model (1) is illustrated in Fig. 11b. Using a two parameter variation we obtained that limit cycles occur when \(g_{11}\in [1.099\;\; 1.161048]\) and \(g_{22}\in [-0.6104841\;\; 0)\). Recall that negative real-valued for kinetic orders describe inhibition activity. For the second case, the bifurcation parameter was \(g_{22}\). The other parameters were: \(g_{11}=0.90\), \(g_{21} =1\) and \(g_{12}=-0.3\) (the smallest/largest allowable values for \(g_{21}\) and \(g_{12}\) are 0.2 and \(-0.1\) respectively, after that the system does not present oscillations).
Figure 12 shows the diagram of the variation of the equilibrium point and the Hopf bifurcation. Notice that for values of \(g_{11}\) less than 0.90 the Hopf bifurcation was not found. Fig. 12a, b show some of the bifurcation dynamics: when parameter \( g_ {22}\) decreases then the stability region also decreases, and the instability region increases (see red and black lines). In such analysis, we obtained that limit cycles occur when \(g_{11}\in [0.90\;\; 1.161]\) and \(g_{22}\in [-0.61\;\; 2.0]\), with \(g_{12}\in [-1.0\;\; -0.1]\) and \(g_{21}\in [0.2\;\; 1.0]\). We also analyzed the oscillations frequency for parameter values close to the bifurcation, which allowed us to classify them in three stage: (a) If \(g_{12}\in [-0.3\;\; -0.1]\) the BMU is less active, that is BMU has long periods of inactivity (adulthood stage); (b) if \(g_{12}\in [-0.7\; \; -0.3)\) the BMU is more active, that is, the period of activity is approximately of 6 months (young adult stage), (c) finally if \(g_{12}\in [-1.0\; -0.7)\) the BMU is more active and does not have inactive periods, that is, BMU is constantly remodeling (childhood stage). Therefore, with all the previous information we were able to classify the BMU behavior for three different stages in Table 1.
Proof of Theorem 3
The existence of optimal solutions for control problem (9)–(12) is obtained if the sufficient conditions of the Filippov-Cesari theorem (Fleming and Rishel 2012) are fulfilled:
- (i):
-
The right-hand side of the model (10) is composed of continuous functions, and for each one of these functions \(f_{i}\) there exist positive constant \({\mathcal {C}}_{1}\), \({\mathcal {C}}_{2}\) such that \(\mid f_{i}(t,x,u)\mid \le {\mathcal {C}}_{1}(1+\mid x\mid +\mid u\mid )\) and \(\mid f_{i}(t,{\overline{x}},u)-f_{i}(t,x,u)\mid \le {\mathcal {C}}_{2}\mid {\overline{x}}-x\mid (1+\mid u\mid )\) for all \(0\le t\le t_{f}\) and \(i=1,2,3\) and \(x(t)=(C(t),B(t),T(t))\).
- (ii):
-
A solution of the dynamical system (10) is well defined and is unique for an admissible \(u\in \varGamma \).
- (iii):
-
The set of solutions to system (10) is non-empty and bounded for admissible control functions \(u\in \varGamma \).
- (iv):
-
The control set \(\varGamma \) is closed, bounded and convex in \(\mathrm{I\!R}\).
- (v):
-
The right-hand side of the dynamical system (10) is linear in control u.
- (vi):
-
The integrand of function (9) is convex with respect to u and satisfies
$$\begin{aligned} T(t)+\frac{B}{2}u^{2}(t)\ge {\mathcal {K}}_{1}\mid u\mid ^{\theta }-{\mathcal {K}}_{2}, \end{aligned}$$with constants \({\mathcal {K}}_{1}>0\), \(\theta >1\) and \({\mathcal {K}}_{2}\).
Item (i) holds since the model functions are of class \(C^2\) in \(\varOmega \). Item (ii) holds since the admissible control set \(\varGamma \) contains continuous bounded functions and the right-hand side of (10) is Lipschitz continuous with respect to the three variables C, B and T for admissible \(u(t)\in \varGamma \). Using Picard-Lindelöf theorem, there exists a unique solution \((C(t), B(T), T(t))\in \varOmega \) corresponding to the admissible control \(u(t):\mathrm{I\!R}^{+}\mapsto [0,u_{c}]\). When the control variable takes its minimum value, that is, \(u(t)=0\) in (10), we recover the initial model without control (4) whose orbits C(t), B(t) and T(t) of \((C(0),B(0), T(0))\in \varOmega \) are bounded for all \(t\ge 0\). Therefore, solutions of the system (10) with \(u(t)=0\) can be regarded as its super-solution. On the other hand, when the control variable is at the upper bound, that is, \(u(t)=u_{c}\), the underlying solution of the system (10) can be regarded as its sub-solutions. Moreover, applying the Carathéodory’s existence theorem guarantees the existence of solutions for Cauchy problems. The latter implies that item (iii) holds. Additionally, by the definition of the admissible control set \(\varGamma \) in (12) is clear that this set control is closed, bounded and convex in \(\mathrm{I\!R}\). Thus, (iv) holds. To proof the item (v), let f(t, x, u) be the vector function defined by right-hand side of (10), we will find suitable bounds for the states:
On the other hand,
where \(m_{2}:=(C_{max})^{g_{21}}\). Finally,
Thus, from (18)–(20) we have that our model is bounded by a linear system. Item vi), the integrand of (9) is quadratic in u, and therefore convex. Condition \(T(t)+\frac{B}{2}u^{2}(t)\ge {\mathcal {K}}_{1}\mid u\mid ^{\theta }-{\mathcal {K}}_{2}\) is fulfilled with \({\mathcal {K}}_{2}=0\), \(\theta =2>1\) and \({\mathcal {K}}_{1}=\frac{B}{2}>0\).
Rights and permissions
About this article
Cite this article
Jerez, S., Pliego, E., Solis, F.J. et al. Antigen receptor therapy in bone metastasis via optimal control for different human life stages. J. Math. Biol. 83, 44 (2021). https://doi.org/10.1007/s00285-021-01673-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00285-021-01673-4